Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD

In a multinational placebo‐controlled phase III clinical trial in 2,185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, treatment with the Nrf2 activator bardoxolone methyl increased estimated glomerular filtration rate, a measure of kidney function, but also resulted in i...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Transl Sci
Päätekijät: Lewis, James H., Jadoul, Michel, Block, Geoffrey A., Chin, Melanie P., Ferguson, Deborah A., Goldsberry, Angie, Meyer, Colin J., O’Grady, Megan, Pergola, Pablo E., Reisman, Scott A., Wigley, W. Christian, Chertow, Glenn M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7877861/
https://ncbi.nlm.nih.gov/pubmed/32860734
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12868
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia